Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib

Dogan E, Erbil Doğan, Erbil Dogan, Uğur Saygılı, Saygili U, Uğur Saygili, Cemal Posacı, Posaci C, Cemal Posaci, Burçin Tuna, Tuna B, Burcin Tuna, Sezer Caliskan, Caliskan S, Sezer Çalışkan, Sabahattin Altunyurt, Saatli B, Bahadir Saatli, Bahadır Saatli
Fertility and Sterility · 2004 · vol. 82 , pp. 1115–1120 · doi:10.1016/j.fertnstert.2004.06.033 · PMID:15474083 · W2102019784
article OA: bronze CC0 ⤵ 71 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Rofecoxib, a cyclooxygenase-2 inhibitor, was administered to rats with endometrial explants and resulted in the regression of these explants.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo investigate the effects of cyclooxygenase-2 (COX-2) inhibitor rofecoxib on endometrial explants and on peritoneal vascular endothelial growth factor (VEGF) levels in the rat endometriosis model.DesignProspective, placebo-controlled study.SettingLaboratory at Dokuz Eylül University.Animal(s)Twenty-six rats with experimentally induced endometriosis.Intervention(s)Rats were treated for 3 weeks with oral rofecoxib (3 mg/kg per day; n = 9); single subcutaneous injection of depot leuprolide acetate (1 mg/kg; n = 9); or vehicle (control; n = 8).Main outcome measure(s)Change in explant area and histologic examination by semiquantitative analysis of endometriotic explants and measurement of peritoneal VEGF levels.Result(s)Three weeks of treatment with rofecoxib statistically significantly decreased the implant size (62.4%) compared with control (16.6%), and this effect was comparable with the decrease in leuprolide (64.3%). Histologic examination of the explants indicated mostly atrophy and regression in treatment groups, and semiquantitative analysis showed statistically significantly lower scores in rats treated with rofecoxib and leuprolide compared with controls. Both rofecoxib and leuprolide statistically significantly decreased VEGF levels compared with controls.Conclusion(s)Rofecoxib causes regression and atrophy of the endometriotic lesions and is as effective as a GnRH agonist with an accompanying decrease in the VEGF levels.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Cyclooxygenase Inhibitors Endometriosis Lactones Administration, Oral Animals Ascitic Fluid Ascitic Fluid Atrophy Cyclooxygenase Inhibitors Endometriosis Endometriosis Endometriosis Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Injections, Subcutaneous Lactones Lactones Leuprolide Leuprolide

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (47)

Cited by (50)

Source provenance

europepmc
last seen: 2026-07-29T06:27:48.050232+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:26.305326+00:00
License: CC0 · commercial use OK